CD79A and familial pancreatic carcinoma: Additionally, our colleagues discovered that IgA+ B cells, which expressed PD-L1, IL-10 and Fas-L, could suppress anti-tumor immunity in oxaliplatin-treated pancreatic cancer [41], one of the mechanisms responsible for chemotherapy tolerance.